Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11) - Test2 - elhamkhani - TriplyDB

Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11)

Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11)

http://www.wikidata.org/entity/Q28538279

about

Management of HIV Infection during Pregnancy in the United States: Updated Evidence-Based Recommendations and Future Potential Practices Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?Safety of pediatric HIV elimination: the growing population of HIV- and antiretroviral-exposed but uninfected infants EUROmediCAT signal detection: an evaluation of selected congenital anomaly-medication associations Surveillance monitoring for safety of in utero antiretroviral therapy exposures: current strategies and challenges.Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ir Placental transfer of darunavir in an ex vivo human cotyledon perfusion model.Birth defects in a cohort of infants born to HIV-infected women in Spain, 2000-2009.In utero exposure to zidovudine and heart anomalies in the ANRS French perinatal cohort and the nested PRIMEVA randomized trial.No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception.HIV-1 proteins, Tat and gp120, target the developing dopamine system Neurologic Outcomes in HIV-Exposed/Uninfected Infants Exposed to Antiretroviral Drugs During Pregnancy in Latin America and the Caribbean.Zidovudine use in pregnancy and congenital malformations.No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects.Comprehensive review of telbivudine in pregnant women with chronic hepatitis B.A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans.Disclosing in utero HIV/ARV exposure to the HIV-exposed uninfected adolescent: is it necessary?Developmental delay and behavioral disorders in 59 HIV-exposed uninfected infants.Tolerance of the newborn to antiretroviral drug exposure in utero.Efavirenz-based antiretroviral therapy versus nevirapine-including regimens for prevention of mother-to-child transmission of HIV option B plus in resource-limited settings: is there anything missing?Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women.Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.

P2860

Q26738453-89DAD963-404F-4A08-A505-BD12D20978D8 Q26765043-C228B8DA-CD39-47E7-8879-A1D575D117C8 Q28538275-896975D0-319F-4A54-BF28-1C5BE33BFFE4 Q28817912-F4DE2B23-5BE1-4399-BD09-1B29C49A6C34 Q30244368-D0F7254F-D973-4205-B5EF-1F0086679CEA Q30249113-18105E19-8C18-44A9-ABC0-31397B448853 Q31043161-3C8677B8-C123-4CEC-A2E4-95CF5B28A076 Q34057304-AE5733B7-E359-4490-A7A8-A9D525F28716 Q34979228-C7F8BF78-5359-42E7-8C74-648BECAE0B56 Q35594678-AB96CD0C-5E5A-43D7-8632-C21007910DF3 Q35703796-0E2D5827-2680-48C7-971F-69BCD12E6249 Q35743630-EB1D4CFB-3DAD-418F-8B2D-507202B2FC6E Q35924264-6252FD9D-A8AA-4254-948B-814051783073 Q36379162-B3A66C5A-D574-49DB-9099-DAD1952C1E5F Q36439051-600E285A-D5D9-4AC2-A443-279A757345B2 Q36727510-69C05CE2-6BD7-48A1-868D-1AD706461264 Q37305526-D5DA040B-A95E-41A5-9064-9A0252D7814D Q37342120-21EB84FB-7C4A-497E-A9F8-0B34FDD7CD84 Q37597830-BF60FB99-5043-4BB2-9F4A-E39C7AAD712D Q38366365-AA13A2DA-C223-4998-A6DF-CC6DC0EE0BEE Q38630880-A322104E-D3D0-4B80-AF29-D1A253468A71 Q38750453-A5B6EB48-C37E-434A-9FAD-DF5948A1C928 Q38828635-11847A5C-C94D-47D7-B72D-6CF7954B98E1 Q38909409-6628C5C6-7FA5-483F-AE12-48B10CFB8261

P2860

Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11)

http://www.wikidata.org/entity/Q28538279

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Association between prenatal e ...... l cohort study (ANRS CO1/CO11)

@ast

Association between prenatal e ...... l cohort study (ANRS CO1/CO11)

@en

Association between prenatal e ...... l cohort study (ANRS CO1/CO11)

@nl

type

label

Association between prenatal e ...... l cohort study (ANRS CO1/CO11)

@ast

Association between prenatal e ...... l cohort study (ANRS CO1/CO11)

@en

Association between prenatal e ...... l cohort study (ANRS CO1/CO11)

@nl

prefLabel

Association between prenatal e ...... l cohort study (ANRS CO1/CO11)

@ast

Association between prenatal e ...... l cohort study (ANRS CO1/CO11)

@en

Association between prenatal e ...... l cohort study (ANRS CO1/CO11)

@nl

P1433

Q28538279-D4FA099B-D330-434D-9CA8-D5E3377E5100

P1476

Q28538279-7785830F-F6B2-4BF8-8D69-11AD7884ED23

P2093

Q28538279-25D1370B-D0A4-419E-87D4-8663CB612087

Q28538279-266E02EE-1AE1-4D03-9BA2-53CDB56FA47D

Q28538279-2BD88B73-7A05-42F3-A37E-D8647FAB46F3

Q28538279-40133EDB-7B4E-4C78-87BA-9406F2EADB81

Q28538279-620BD506-E427-4AFD-BD93-81329E44B228

Q28538279-8B192403-BAC8-43A5-999F-EF2B9243109E

Q28538279-8E4FC2BE-04D2-49EC-B13D-8A8CB4FD7162

Q28538279-96E17468-C54B-4534-83CA-BF11296CBC82

Q28538279-AF92605F-4FC1-4F3A-A240-7CA273EC84C6

Q28538279-EA3970A9-AE1E-4BC4-9A68-F4DB10B0837F

P2860

Q28538279-0216AEC1-A909-40E2-9C6A-2474DC99C07F

Q28538279-06134407-46FC-4E94-B569-B0B1AEA4F839

Q28538279-0A04C6B4-92D6-4688-82A8-567F5ACCE556

Q28538279-0C8605CB-8340-4C5B-AD51-E910DA03544E

Q28538279-213E0C50-3CA6-4E00-80F5-D15804CC61F2

Q28538279-287CDB6A-0F22-46C0-B759-5AA3549D37D6

Q28538279-28EF3A48-BEE4-43A4-AF6E-7D22D90EEEF6

Q28538279-52F87906-C61A-4956-98F6-CCC0BD15A866

Q28538279-6FE758E3-AEA7-4A78-8F60-185325CE5B81

Q28538279-7ABA602F-0449-456A-BEB9-C113953B6E77

P304

Q28538279-97274AFA-65CA-468B-8B9B-4D27ED9BE845

P31

Q28538279-C40B02B8-5D37-4AF7-AE9F-3E71E83884D6

P3181

Q28538279-1286937E-AB84-4807-9E4B-AE558EF3C169

P356

Q28538279-697E9F71-93D5-4165-BAB7-8D0A91A24A36

P407

Q28538279-DEAEB632-4AA9-4539-91C0-1B1779568FBA

P433

Q28538279-3D5C77A3-2802-4676-832C-7FA4C41C2EFE

P478

Q28538279-D3C27DCE-A9B4-4BB6-86B1-15F6FE2B1F57

P50

Q28538279-7CA7041F-83A2-440D-AADA-12AB114851BD

Q28538279-EEB58CDC-11B4-46AF-B434-270C8A6BE034

P577

Q28538279-D21A953C-DCFF-4A93-BB98-E5B3068C3423

P5875

Q28538279-FE57C5CD-401C-4A2E-864D-5EDFAA98476F

P698

Q28538279-78F2D26A-A212-4F72-BBF8-5C4F9488D857

P921

Q28538279-618D7E80-7DB7-4A2E-A27F-A1C6A5F71E5A

P932

Q28538279-0936B8C0-1751-47CD-BE18-3912365BF441

P3181

P356

JOURNAL.PMED.1001635

P1433

P1476

Association between prenatal e ...... l cohort study (ANRS CO1/CO11)

@en

P2093

Albert Faye

http://www.w3.org/2001/XMLSchema#string

Catherine Dollfus

http://www.w3.org/2001/XMLSchema#string

Damien Bonnet

http://www.w3.org/2001/XMLSchema#string

Jeanne Sibiude

http://www.w3.org/2001/XMLSchema#string

Josiane Warszawski

http://www.w3.org/2001/XMLSchema#string

Jérôme Le Chenadec

http://www.w3.org/2001/XMLSchema#string

Laurent Mandelbrot

http://www.w3.org/2001/XMLSchema#string

Naima Boullag-Bonnet

http://www.w3.org/2001/XMLSchema#string

Nathalie Lelong

http://www.w3.org/2001/XMLSchema#string

Roland Tubiana

http://www.w3.org/2001/XMLSchema#string

P2860

No adjustments are needed for multiple comparisons

Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities?

Prenatal zidovudine use and congenital anomalies in a medicaid population.

Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed infants

Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.

Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study.

Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C.

Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.

Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy.

Myelomeningocele in an infant with intrauterine exposure to efavirenz.

P304

e1001635

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4507909

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PMED.1001635

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Catherine Dollfus

Babak Khoshnood

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261997379

http://www.w3.org/2001/XMLSchema#string

P698

24781315

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

4004551

http://www.w3.org/2001/XMLSchema#string